Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Why Mutant-Selective EGFR Inhibition Needs Context
2026-11-16
EAI045 is documented as an allosteric inhibitor that preferentially targets selected drug-resistant EGFR mutants. Its reported biochemical potency does not translate directly into tumor regression: cellular signaling state, receptor context and antibody combination all affect the observed outcome.
What 5-EdU Can—and Cannot—Show in SCI
2026-11-16
A source-grounded interpretation of 5-EdU as a DNA-synthesis readout in spinal cord injury research, separating cell-cycle measurement from evidence for glial mechanism, tissue repair, and functional recovery.
When Context Changes a Histology Result
2026-11-15
Hematoxylin can provide nuclear and tissue contrast, but the biological meaning of a histological result depends on the model, comparator, developmental stage, proxy exposure, and independent readouts. A neonatal pig study illustrates how morphology, FOXA2 localization, and transcriptomics can support an association without proving a single causal mechanism.
What Does Oleoylcarnitine Signal in Liver Metabolism?
2026-11-14
Oleoylcarnitine is best interpreted as a metabolic signal of disrupted long-chain fatty-acid handling, particularly when fatty acid β-oxidation is impaired. Its proposed connection to hepatocellular carcinogenesis is hypothesis-generating rather than proof that the metabolite independently causes liver cancer.
How Receptor Actions Shape GI Readouts
2026-11-13
A receptor-to-physiology framework for interpreting metoclopramide’s documented mechanism, gastrointestinal contexts, and the limits of product-level evidence.
What Shikimic Acid Cell Evidence Means
2026-11-13
Shikimic acid has a defined role as a shikimate pathway intermediate and a separate, model-specific association with reduced oxidative-stress readouts in SH-SY5Y cells. Together, these facts support a focused cellular antioxidant observation, but they do not establish a direct molecular mechanism or organism-level neuroprotection.
What Multiplex CRISPR Evidence Shows
2026-11-12
Multiplexed CRISPR–Cas systems can perturb several genomic targets at once, producing coordinated gene disruption, structural variation, transcriptional regulation, or cell-state changes. The strongest evidence supports technical flexibility and mechanistic plausibility, while delivery, off-target activity, repair outcomes, and translation remain context-dependent.
How Broad Is ACA’s Reported Channel Block?
2026-11-12
The reported findings show that N-(p-amylcinnamoyl) anthranilic acid affects several ion-channel readouts, but the results do not support treating every effect as evidence of one universal mechanism. Comparing calcium signals, ionic currents, and cardiac-cell responses clarifies both its value as a pharmacological probe and the limits of target attribution.
What Demecycline Readouts Can Actually Show
2026-11-11
Demecycline is documented as a C6 demethylated tetracycline derivative and bacterial protein synthesis inhibitor. Its class-level mechanism can explain why bacterial growth signals may change, but those signals alone do not establish activity in a respiratory infection model, pneumonia, or clinical treatment.
What Does TAB1 Antibody Detection Show?
2026-11-11
TAB1 antibody detection can reveal the presence, distribution, or molecular association of TAB1, but it is not a direct measurement of TGF-β or MAPK pathway activity. The scientific value of the signal depends on whether the readout concerns protein abundance, localization, or complex formation.
How TAS-102 Links DNA Damage to Signaling
2026-11-10
TAS-102 is described as a two-component nucleoside combination whose principal cytotoxic logic begins with trifluridine triphosphate incorporation into DNA and extends to cell-cycle and signaling responses. The documented mechanism supports a coherent molecular-to-cellular model, while its antiangiogenic interpretation remains a downstream hypothesis rather than a demonstrated outcome in a defined biological model.
How Olanzapine Links Receptors and Cell Phenotypes
2026-11-10
Olanzapine connects multi-receptor pharmacology with distinct brain and glioblastoma-cell readouts, but those findings represent different biological evidence levels rather than one established mechanism.
What Does Rosuvastatin Calcium Show?
2026-11-09
Rosuvastatin Calcium is most informative as a molecular probe of HMG-CoA reductase and cholesterol biosynthesis. The mechanistic link to pathway flux is clear in principle, but enzyme, cellular, circulating-lipid and cardiovascular readouts answer different research questions and should not be treated as interchangeable.
How DMG-PEG2000-Biotin Connects Surface to Signal
2026-11-09
DMG-PEG2000-Biotin combines a lipid-associated anchor, a PEG2000 spacer, and a biotin recognition group. Its documented architecture supports a conceptual link between lipid-particle interfacial behavior and streptavidin-mediated detection, while product-specific delivery or assay performance remains unquantified.
What Does 5-HTP Identity Tell Us?
2026-11-08
5-HTP is a biochemical precursor in serotonin synthesis, so its documented identity supports a mechanistic interpretation of the pathway but not a product-specific claim about biological effects. The key distinction is between chemical identity, enzyme conversion, downstream signaling, and measured outcomes.